EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology‐Specific End‐Stage Liver Disease

Thomas Nicholson, Sophie L Allen, Jonathan I Quinlan, Amritpal Dhaliwal, Michael Macleod, Joshua Price, Jon Hazeldine, Michael S Sagmeister, Caitlin Ditchfield, Kirsty C McGee, Felicity R Williams, Ahmed M Elsharkawy und 5 weitere

Journal of Cachexia, Sarcopenia and Muscle · 2026-06 · 17 (3)

DOI: 10.1002/jcsm.70294 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 26.04.2026. Verfasst von Thomas Nicholson und 16 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK. Hauptthemen laut MEDLINE: End Stage Liver Disease, Sarcopenia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Birmingham Biomedical Research Centre, Birmingham, UK, Birmingham Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with end‐stage liver disease (ESLD) often present with sarcopenia, defined as loss of skeletal muscle mass and quality, which is associated with reduced quality of life and increased mortality. However, the molecular mechanisms driving sarcopenia in ESLD are not fully understood and there are currently no therapeutic interventions. This study aimed to identify potential circulating factors contributing to sarcopenia progression in ESLD by assessing their role in driving transcriptomic alterations in skeletal muscle.

Methods

Quadriceps muscle tissue, plasma and serum were obtained from ESLD patients ( n = 24) and age/sex‐matched healthy controls (HC; n = 18) (Clinical Trial ID: NCT04734496, Ethical Approval 18/WM/0167). Total RNA from snap‐frozen vastus lateralis muscle biopsies underwent RNA sequencing (Illumina). Serum concentrations of 60 cytokines were profiled by Luminex and ELISA, with comparisons made both between ESLD and HC, and across ESLD aetiologies (alcohol‐related, NAFLD, viral hepatitis, other). In vitro, primary human myotubes (from non‐ESLD aged donors, NRES #16/SS/0172) were treated with 10% ESLD or HC plasma (24 h, n = 6 per group) followed by RNA sequencing (BGI Genomics). Differentially expressed genes ( p < 0.05, fold‐change > 1.5) were identified via Qlucore and DESeq2, and pathway analysis performed using Ingenuity (Qiagen). The impact of physiological concentrations of candidate cytokines (IL‐1α, GDF‐15 and HGF) on myotube thickness, differentiation and mitochondrial function was assessed by immunofluorescence microscopy, RT‐qPCR and metabolic flux assays.

Results

In ESLD muscle, 387 and 225 genes were significantly up‐ and downregulated compared to HC, respectively, with cellular senescence identified as a top dysregulated function. Upstream regulator analysis predicted activation of hepatocyte growth factor (HGF) and interleukin‐1 signalling. Subgroup analysis revealed distinct transcriptomic profiles based on disease aetiology. Serum profiling identified 15 cytokines significantly elevated ( p < 0.05) and five reduced ( p < 0.05) in ESLD, including increased HGF and reduced interleukin‐1 receptor antagonist. Stratified analysis also revealed aetiology specific cytokine profiles, with only GDF‐15 significantly ( p < 0.0001) elevated in all groupsTwenty‐four‐hour ESLD plasma treatment induced 423 differentially expressed genes in human myotubes, which were again associated with significant activation of senescence pathways, with IL‐1 identified as a key upstream driver. In vitro, IL‐1α, GDF‐15, and HGF significantly reduced myotube thickness, nuclear fusion index and perturbed metabolism (increased glycolysis, impaired oxidative phosphorylation).

Conclusions

Collectively, these findings suggest that sarcopenia in ESLD is driven by aetiology‐specific mechanisms, highlighting the potential for targeted therapies to improve muscle mass and function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

End Stage Liver DiseaseSarcopeniaAgedFemaleHumansMaleMiddle AgedBiomarkersCytokinesMuscle, Skeletal

Stichwörter der Autor:innen

cytokinesend‐stage liver diseasehuman myotubessarcopeniaskeletal muscle

Substanzen

BiomarkersCytokines

Autor:innen und Institutionen

  • National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK.
  • Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
  • School of Sport, Exercise and Rehabilitation Science, University of Birmingham, Birmingham, UK.
  • Liver Transplant Unit, Queen Elizabeth Hospital, Birmingham, UK.
  • Department of Metabolism and Systems Science, School of Medical Sciences, University of Birmingham, Birmingham, UK.

ORCID-Profile: Simon W Jones

Förderung

  • NIHR Birmingham Biomedical Research Centre, Birmingham, UK
  • Birmingham Biomedical Research Centre

Zitieren

APA

Nicholson, T., Allen, S. L., Quinlan, J. I., Dhaliwal, A., Macleod, M., Price, J., Hazeldine, J., Sagmeister, M. S., Ditchfield, C., McGee, K. C., Williams, F. R., Elsharkawy, A. M., Armstrong, M. J., Greig, C. A., Lord, J. M., Breen, L., & Jones, S. W. (2026). Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology‐Specific End‐Stage Liver Disease. Journal of Cachexia, Sarcopenia and Muscle, 17(3). https://doi.org/10.1002/jcsm.70294

Vancouver

Nicholson T, Allen SL, Quinlan JI, Dhaliwal A, Macleod M, Price J, et al. Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology‐Specific End‐Stage Liver Disease. Journal of Cachexia, Sarcopenia and Muscle. 2026;17(3). doi:10.1002/jcsm.70294

BibTeX
@article{Nicholson2026,
  author = {Nicholson, Thomas and Allen, Sophie L and Quinlan, Jonathan I and Dhaliwal, Amritpal and Macleod, Michael and Price, Joshua and Hazeldine, Jon and Sagmeister, Michael S and Ditchfield, Caitlin and McGee, Kirsty C and Williams, Felicity R and Elsharkawy, Ahmed M and Armstrong, Matthew J and Greig, Carolyn A and Lord, Janet M and Breen, Leigh and Jones, Simon W},
  title = {Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology‐Specific End‐Stage Liver Disease},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2026},
  volume = {17},
  number = {3},
  doi = {10.1002/jcsm.70294}
}
Kostenlos starten →